Experimental studies in AD mouse models have demonstrated that B2M reduction—achieved through genetic ablation, antisense oligonucleotide (ASO) administration, or antibody-based interventions—markedly attenuates cognitive deficits and reduces amyloid plaque burden [10]. This evidence concerns the gene B2M and Alzheimer disease.